Evaluation of Long-Term Outcomes of Direct Acting Antiviral Agents in Chronic Kidney Disease Subjects: A Single Center Cohort Study

Evaluation of Long-Term Outcomes of Direct Acting Antiviral Agents in Chronic Kidney Disease Subjects: A Single Center Cohort Study

Background: The chronic kidney disease (CKD) population, including kidney transplant recipients (KTRs) and subjects on renal replacement therapy, is particularly vulnerable to unfavorable outcomes from chronic hepatitis C (CHC). Currently, there are oral direct-acting antiviral agents (DAAs) availab...

Full description

Bibliographic Details
Main Authors:	Paulina Czarnecka, Kinga Czarnecka, Olga Tronina, Teresa Bączkowska, Aleksandra Wyczałkowska-Tomasik, Magdalena Durlik, Katarzyna Czerwinska
Format:	Article
Language:	English
Published:	MDPI AG 2023-05-01
Series:	Journal of Clinical Medicine
Subjects:	hepatitis C infection (HCV) chronic infection liver fibrosis direct-acting antiviral agents (DAA) occult hepatitis C infection treatment efficacy
Online Access:	https://www.mdpi.com/2077-0383/12/10/3513

Similar Items

Are We on the Right Track for HCV Micro-Elimination? HCV Management Practices in Dialysis Centers in Poland—A National Cross-Sectional Survey
by: Paulina Czarnecka, et al.
Published: (2023-04-01)

New treatment of hepatitis C (Direct Acting Antiviral)
by: Mohsen Akhondi-Meybodi
Published: (2019-10-01)

Direct-Acting Antiviral Agents for Hepatitis C Virus Infection—From Drug Discovery to Successful Implementation in Clinical Practice
by: Christopher Dietz, et al.
Published: (2022-06-01)

Efficacy and safety of direct-acting antiviral therapy in previous hard-to-treat patients with recurrent hepatitis C virus infection after liver transplantation: a real-world cohort
by: Bernuth S, et al.
Published: (2017-07-01)

Risk Factors Contributing to the Occurrence and Recurrence of Hepatocellular Carcinoma in Hepatitis C Virus Patients Treated with Direct-Acting Antivirals
by: Sara Kishta, et al.
Published: (2020-06-01)

Hepatocellular Carcinoma Recurrence after Hepatitis C Virus Therapy with Direct-Acting Antivirals. A Systematic Review and Meta-Analysis
by: Leonardo Frazzoni, et al.
Published: (2021-04-01)

Utilization of HCV viremic donors in kidney transplantation: a chance or a threat?
by: Paulina Czarnecka, et al.
Published: (2022-12-01)

Efficacy and Safety of Direct-Acting Antiviral Therapy in Patients With Chronic Hepatitis C Virus Infection: A Real-World Single-Center Experience in Tianjin, China
by: Huan Xia, et al.
Published: (2020-05-01)

Prevalence and effect of occult hepatitis C infection in patients with persistent liver enzyme elevation after achieving 24 weeks of sustained virological response
by: Anwar A Mohamed, et al.
Published: (2019-01-01)

Trends in long‐term outcomes of patients with HCV‐associated hepatocellular carcinoma after hepatectomy: A comparison before and after introduction of direct‐acting antivirus therapy
by: Fumiaki Munekage, et al.
Published: (2024-01-01)

Evaluation of impact of occult hepatitis B infection in chronic HCV-infected patients: A retrospective cohort study
by: Mohit Bhatia, et al.
Published: (2018-07-01)

Incidence of depression in patients with hepatitis C treated with direct-acting antivirals
by: Elfi Egmond, et al.

A clinical case of three times treatment of hepatitis C with repeated infection in HIV-positive patient. Case Report
by: Anastasia V. Pokrovskaya, et al.
Published: (2023-12-01)

Liver cirrhosis: dispensary observation, the effectiveness of antiviral therapy
by: Y.H. Yupatau, et al.
Published: (2022-08-01)

Direct-acting antiviral therapy may help restore HCV-induced impaired redox balance and liver fibrosis process
by: Bal Tayibe, et al.
Published: (2022-11-01)

Directly Acting Antiviral-Based Treatment for HCV-Infected Persons Who Inject Drugs: A Multicenter Real-Life Study
by: Vincenzo Messina, et al.
Published: (2020-12-01)

Case report: Chronic hepatitis C with anti-HCV positive and serum HCV RNA negative
by: Huihui Lu, et al.
Published: (2023-04-01)

Access to Hepatitis C Treatment during and after Incarceration in New Jersey, United States: A Qualitative Study
by: Samir Kamat, et al.
Published: (2023-04-01)

Micro-elimination of hepatitis C in patients with chronic kidney disease: an Egyptian single-center study
by: Tari George Michael, et al.
Published: (2022-07-01)

Direct Antiviral Treatments for Hepatitis C Virus Have Off-Target Effects of Oncologic Relevance in Hepatocellular Carcinoma
by: Catia Giovannini, et al.
Published: (2020-09-01)

Transplantation of Organs from Hepatitis C Virus-Positive Donors under Direct-Acting Antiviral Regimens
by: Muhammad Nauman Zahid
Published: (2022-01-01)

A Review on Extrahepatic Manifestations of Chronic Hepatitis C Virus Infection and the Impact of Direct-Acting Antiviral Therapy
by: Cesare Mazzaro, et al.
Published: (2021-11-01)

Sofosbuvir plus velpatasvir for 8 weeks in patients with acute hepatitis C: The HepNet acute HCV-V study
by: Benjamin Maasoumy, et al.
Published: (2023-03-01)

Real‐world effectiveness of direct‐acting antiviral agents for chronic hepatitis C patients with genotype‐2 infection after completed treatment
by: Tzu‐Sheng Cheng, et al.
Published: (2021-04-01)

HCV mono-infected and HIV/HCV co-infected individuals treated with direct-acting antivirals: to what extent do they differ?
by: Giuseppe Bruno, et al.
Published: (2017-09-01)

Real-World Effectiveness and Safety of Direct-Acting Antivirals in Patients with Chronic Hepatitis C and Epilepsy: An Epi-Ter-2 Study in Poland
by: Monika Pazgan-Simon, et al.
Published: (2023-07-01)

The Prevalence and Impact of Hepatic Steatosis on Response to Direct-Acting Antiviral Therapy in HIV–HCV Coinfection
by: Leigh P. Johnson, et al.
Published: (2020-04-01)

Evaluation of the effect of direct-acting antiviral agents on melatonin level and lipid peroxidation in chronic hepatitis C patients
by: Nageh Ahmed El-Mahdy, et al.
Published: (2023-08-01)

Outcome of direct-acting antiviral treatment in patients with hepatitis C virus/hepatitis B virus coinfection
by: El-Araby Mohamed Ibrahim Shalaby, et al.
Published: (2023-06-01)

Prevalence of resistance-associated substitutions to direct-acting antiviral agents in hemodialysis and renal transplant patients infected with hepatitis C virus
by: Tavares RCF, et al.
Published: (2018-10-01)

Effectiveness of direct-acting antivirals in Hepatitis C virus infection in haemodialysis patients
by: Soraya Abad, et al.
Published: (2017-03-01)

Successful HCV Therapy Reduces Liver Disease Severity and Inflammation Biomarkers in HIV/HCV-Coinfected Patients With Advanced Cirrhosis: A Cohort Study
by: Luz Maria Medrano, et al.
Published: (2021-02-01)

Hepatitis C Clearance by Direct-Acting Antivirals Impacts Glucose and Lipid Homeostasis
by: Christiana Graf, et al.
Published: (2020-08-01)

Bioequivalent pharmacokinetics for generic and originator hepatitis C direct-acting antivirals
by: Andrew Hill, et al.
Published: (2018-04-01)

LONG TERM FOLLOW UP AFTER HCV CURE WITH DIRECT ACTING ANTIVIRALS – REVIEW OF THE LITERATURE
by: Andreea Ruxandra Cazan, et al.
Published: (2018-12-01)

Resistance Mutations A30K and Y93N Associated with Treatment Failure with Sofosbuvir and Daclatasvir for Hepatitis C Virus Infection Non-Responder Patients: Case Reports
by: Vanessa D. Costa, et al.
Published: (2019-10-01)

Efficacy of treatment with Ombitasvir, Paritaprevir / r + Dasabuvir over 8 versus 12 weeks in chronic HCV hepatitis genotype 1b
by: Mircea Manuc, et al.
Published: (2021-03-01)

Liver Fibrosis Regression and Associated Factors in HCV Patients Treated with Direct-Acting Antiviral Agents
by: Naim Abu-Freha, et al.
Published: (2023-09-01)

HCC in the Era of Direct-Acting Antiviral Agents (DAAs): Surgical and Other Curative or Palliative Strategies in the Elderly
by: Stefania Brozzetti, et al.
Published: (2021-06-01)

Baseline Plasma Metabotype Correlates With Direct-Acting Antiviral Therapy Nonresponse for HCV in HIV–HCV Coinfected Patients
by: Gaurav Tripathi, et al.
Published: (2022-01-01)